Octavio Espinoza - 23 Dec 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Financial Officer
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol: LGND
Transactions as of: 23 Dec 2024
Net transactions value: -$244,850
Form type: 4
Filing time: 26 Dec 2024, 20:32:43 UTC
Previous filing: 06 Dec 2024
Next filing: 19 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Sale	$244,850	-2,104	-9.2%	$116.37	20,647	23 Dec 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.33 to $116.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.33 to $116.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.